Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma

No abstract is available for this paper.

• Publication year

  2011

• Venue

  World journal of urology

• Publication date

  2011-04-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00345-011-0673-4PMID 21461939
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

  2010cited by this paper
• Is advanced renal cell carcinoma becoming a chronic disease?

  2010cited by this paper
• Is advanced renal cell carcinoma becoming a chronic disease

  2010cited by this paper
• Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

  2009cited by this paper
• Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

  2009cited by this paper
• 252 RETROSPECTIVE ANALYSIS OF THE SEQUENTIAL USE OF SORAFENIB AND SUNITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)

  2009cited by this paper
• Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

  2009cited by this paper
• 7137 Final analysis of a large open-label, noncomparative, phase 3 study of sorafenib in European patients with advanced RCC (EU-ARCCS)

  2009cited by this paper
• Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

  2009cited by this paper
• Sequential sorafenib and sunitinib for renal cell carcinoma.

  2009cited by this paper
• Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.

  2008cited by this paper
• Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.

  2008cited by this paper

• Cost-effectiveness Analysis of Sunitinib and Sorafenib Sequential Treatment of Metastatic Renal Cell Carcinoma

  2017cites this paper
• Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis

  2017cites this paper
• Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.

  2016cites this paper
• The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma

  2016cites this paper
• Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy

  2015cites this paper
• Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study

  2014cites this paper
• Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies.

  2013cites this paper
• Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008)

  2013cites this paper
• Hijacking the vasculature in ccRCC—co-option, remodelling and angiogenesis

  2013cites this paper
• Comparing how significantly the pharmacological treatment of genitourinary cancer in a non-curative setting affects endpoints of survival or response

  2013cites this paper
• Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.

  2013cites this paper
• What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?

  2013cites this paper
• Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement

  2012cites this paper
• Sorafenib rechallenge in patients with metastatic renal cell carcinoma

  2012cites this paper
• A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma

  2012cites this paper
• Second-line systemic therapy for the treatment of metastatic renal cell cancer

  2012cites this paper
• Sorafenib for the treatment of renal cancer

  2012cites this paper
• Systemische und operative Therapie des metastasierten Nierenzellkarzinoms

  2012cites this paper
• Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI

  2012cites this paper
• [Systemic and surgical management of metastatic renal cell carcinoma].

  2012cites this paper
• Sitzungsbericht der AG Uropathologie

  2012cites this paper
• Renal cell carcinoma: resistance to therapy, role of apoptosis, and the prognostic and therapeutic target potential of TRAF proteins.

  2012cites this paper
• Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study

  2012cites this paper
• Systemic therapy in renal cell carcinoma: advancing paradigms.

  2012cites this paper
• Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.

  2011cites this paper
• Sitzungsbericht der AG Uropathologie

  2010cites this paper